ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT
Orbactiv 400 mg powder for concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains oritavancin diphosphate equivalent to 400 mg oritavancin.
After reconstitution, 1 ml of the solution contains 10 mg oritavancin.
After dilution, 1 ml of the solution for infusion contains 1.2 mg oritavancin.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion (powder for concentrate).
White to off-white powder.

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Orbactiv is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration
Posology
1,200 mg administered as a single dose by intravenous infusion over 3 hours.

Special populations

Elderly (≥ 65 years)
No dosage adjustment is required for patients ≥ 65 years of age (see section 5.2).

Renal impairment
No dosage adjustment is needed in patients with mild or moderate renal impairment (see section 5.2). The pharmacokinetics of oritavancin in patients with severe renal impairment has not been evaluated. Oritavancin is not removed from blood by haemodialysis procedures.

Hepatic impairment
No dosage adjustment is required for patients with mild to moderate hepatic impairment (Child-Pugh
Class B) (see section 5.2). The pharmacokinetics of oritavancin in patients with severe hepatic impairment (Child-Pugh Class C) has not been evaluated.

Paediatric population
The safety and efficacy of oritavancin in children and adolescents (<18 years) has not yet been established. No data are available.

Method of administration
Intravenous use.
Intravenous infusion over 3 hours (see section 6.6).

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

4.3 Contraindications
Hypersensitivity to the active substance or to the excipients listed in section 6.1.

Use of intravenous unfractionated heparin sodium is contraindicated for 48 hours after oritavancin administration because the activated partial thromboplastin time (aPTT) test results are expected to remain falsely elevated for approximately 48 hours after oritavancin administration (see sections 4.4 and 4.5).

4.4 Special warnings and precautions for use

Hypersensitivity reactions
Serious hypersensitivity reactions have been reported with the use of oritavancin. If an acute hypersensitivity reaction occurs during oritavancin infusion, oritavancin should be discontinued immediately and appropriate supportive care should be instituted.

No data are available on cross-reactivity between oritavancin and other glycopeptides, including vancomycin. Before using oritavancin it is important to inquire carefully about previous hypersensitivity reactions to glycopeptides (e.g. vancomycin, telavancin). Due to the possibility of cross-hypersensitivity, there should be careful monitoring of patients with any history of glycopeptide hypersensitivity during and after the infusion.

Infusion related reactions
Oritavancin is given via intravenous infusion over 3 hours to minimise the risk of infusion related reactions. Oritavancin has been shown to cause infusion related reactions including pruritus, urticaria or flushing. If reactions do occur, stopping or slowing the infusion should be considered to mitigate the reaction (see section 4.8).

Need for additional antibacterial agents
Oritavancin is active against Gram positive bacteria only (see section 5.1). In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, oritavancin should be co-administered with appropriate antibacterial agent(s).

Concomitant use of warfarin
Co-administration of oritavancin and warfarin may result in higher exposure of warfarin (resulting in 31% increase in the mean area under the curve (AUC) of warfarin), which may increase the risk of bleeding (see section 4.5). Oritavancin should only be used in patients on chronic warfarin therapy when the benefits can be expected to outweigh the risk of bleeding; these patients should be frequently monitored for signs of bleeding.
Oritavancin has been shown to artificially prolong prothrombin time (PT) and international normalised ratio (INR) for up to 24 hours, making the monitoring of the anticoagulation effect of warfarin unreliable up to 24 hours after an oritavancin dose.

**Interference with assay for coagulation tests**
Oritavancin has been shown to artificially prolong aPTT for 48 hours and the PT and INR for 24 hours by binding to and preventing action of the phospholipid reagents which activate coagulation in commonly used laboratory coagulation tests. For patients who require aPTT monitoring within 48 hours of oritavancin dosing, a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered.

Effects by oritavancin on activated clotting time (ACT) are expected since the phospholipid reagents are also utilized in this coagulation test. Although oritavancin interfered with certain tests used to monitor coagulation, no known effect on the coagulation system has been observed.

**Clostridium difficile-associated diarrhoea**
Antibacterial-associated colitis and pseudomembranous colitis have been reported for oritavancin and may range in severity from mild to life threatening diarrhoea. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of oritavancin (see section 4.8). In such a circumstance, the use of supportive measures together with the administration of specific treatment for *Clostridium difficile* should be considered.

**Superinfection**
The use of antibacterial agents may increase the risk of overgrowth of non-susceptible micro-organisms. If superinfection occurs, appropriate measures should be taken.

**Osteomyelitis**
In Phase 3 ABSSSI clinical trials, more cases of osteomyelitis were reported in the oritavancin-treated arm than in the vancomycin-treated arm (see section 4.8). Patients should be monitored for signs and symptoms of osteomyelitis after administration of oritavancin. If osteomyelitis is suspected or diagnosed, appropriate alternative antibacterial therapy should be instituted.

**Abscess**
In the Phase 3 clinical trials, slightly more cases of newly emergent abscesses were reported in the oritavancin-treated arm than in the vancomycin-treated arm (4.6% vs 3.4%, respectively) (see section 4.8). If newly emergent abscesses occur, appropriate measures should be taken.

**Limitations of the clinical data**
In the two major trials in ABSSSI the types of infections treated were confined to cellulitis, abscesses and wound infections only. Other types of infections have not been studied. There is limited experience in clinical studies in patients with bacteraemia, peripheral vascular disease or neutropenia, in immunocompromised patients, in patients aged > 65 years and in infections due to *S. pyogenes*.

### 4.5 Interaction with other medicinal products and other forms of interaction

**Substances metabolised by cytochrome P450**
A cocktail drug-drug interaction study was conducted in healthy volunteers (n=16) evaluating the concomitant administration of a single 1,200 mg dose of oritavancin with probe substrates for several CYP450 enzymes. Oritavancin was found to be a nonspecific, weak inhibitor (CYP2C9 and CYP2C19) or a weak inducer (CYP3A4 and CYP2D6) of several CYP isoforms. Caution should be used when administering oritavancin concomitantly with medicinal products with a narrow therapeutic window that are predominantly metabolised by one of the affected CYP450 enzymes (e.g., warfarin), as co-administration may increase (e.g., for CYP2C9 substrates) or decrease (e.g., for CYP2D6 substrates) concentrations of the narrow therapeutic range medicinal product. Patients should be closely monitored for signs of toxicity or lack of efficacy if they have been given oritavancin while on a
potentially affected compound (e.g. patients should be monitored for bleeding if concomitantly receiving oritavancin and warfarin) (see section 4.4).

**Drug-Laboratory test interactions**

Oritavancin has been shown to artificially prolong aPTT for 48 hours and PT and INR for up to 24 hours by binding to and preventing action of the phospholipid reagents which activate coagulation in commonly used laboratory coagulation tests. Effects by oritavancin on activated clotting time (ACT) are expected since the phospholipid reagents are also utilised in this coagulation test (see section 4.4).

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**

There are no or limited amount of data from the use of oritavancin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of oritavancin during pregnancy unless the potential benefit justifies the potential risk to the foetus.

**Breast-feeding**

Available pharmacodynamic/toxicological data in animals have shown excretion of oritavancin in milk (see section 5.3). It is unknown whether oritavancin/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from oritavancin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

**Fertility**

Animal studies have revealed no evidence of impaired fertility due to oritavancin at the highest concentrations administered, however, there is no data on the effects of oritavancin on human fertility.

### 4.7 Effects on ability to drive and use machines

Oritavancin has a minor influence on the ability to drive and use machines. Dizziness may occur and this may have an effect on driving and use of machines (see section 4.8).

### 4.8 Undesirable effects

**Summary of the safety profile**

The safety of oritavancin has been evaluated in over 2,400 patients with acute bacterial skin and skin structure infections in clinical studies.

The pooled ABSSSI Phase 3 clinical trials included 976 adult patients who were treated with a single 1,200 mg dose of oritavancin.

The most commonly reported adverse reactions (≥5%) were: nausea, hypersensitivity reactions, infusion site reactions, and headache. The most commonly reported serious adverse reaction was cellulitis (1.1%, 11/976). The most common reported reasons for discontinuation were cellulitis (0.4%, 4/976) and osteomyelitis (0.3%, 3/976). Female patients had a higher reporting rate for adverse reactions than male patients.

**Tabulated list of adverse reactions**

Adverse reactions for oritavancin from the pooled Phase 3 ABSSSI clinical trials with single dose oritavancin are listed by system organ class in the following table.

Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the
available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

**Table 1: Frequency of adverse reactions by system organ class**

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Frequency</th>
<th>Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Cellulitis, abscess (limb and subcutaneous)</td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Osteomyelitis</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Anaemia</td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Eosinophilia, thrombocytopenia</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Hypersensitivity (see sections 4.3 and 4.4)</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Hypoglycaemia, hyperuricaemia</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Headache, dizziness</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Tachycardia</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Nausea, vomiting, diarrhoea, constipation</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Liver function test abnormal (Alanine aminotransferase increased, Aspartate aminotransferase increased)</td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Blood bilirubin increased</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Urticaria, rash, pruritis</td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td>Leucocytoclastic vasculitis, angioedema, erythema multiforme, flushing</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>Infusion site reactions, including the following symptoms infusion site phlebitis, infusion site erythema, extravasation, induration, pruritis, rash, oedema peripheral</td>
</tr>
</tbody>
</table>

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

In the clinical programme of 3,017 oritavancin-treated subjects; there was no incidence of accidental overdose of oritavancin.

Oritavancin is not removed from blood by haemodialysis procedures. In the event of overdose, supportive measures should be taken.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use, glycopeptide antibacterials, ATC code: J01XA05

Mechanism of action
Oritavancin has three mechanisms of action: (i) inhibition of the transglycosylation (polymerization) step of cell wall biosynthesis by binding to the stem peptide of peptidoglycan precursors; (ii) inhibition of the transpeptidation (crosslinking) step of cell wall biosynthesis by binding to the peptide bridging segments of the cell wall; and (iii) disruption of bacterial membrane integrity, leading to depolarization, permeabilization, and rapid cell death.

Resistance
Gram-negative organisms are intrinsically resistant to all glycopeptides, including oritavancin.

Resistance to oritavancin was observed in vitro in vancomycin-resistant isolates of *Staphylococcus aureus*. There is no known cross-resistance between oritavancin and non-glycopeptide classes of antibiotics.

Oritavancin exhibits reduced in vitro activity against certain Gram-positive organisms of the genera *Lactobacillus*, *Leuconostoc* and *Pediococcus* that are intrinsically resistant to glycopeptides.

Susceptibility testing break points
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:

<table>
<thead>
<tr>
<th>Organism group</th>
<th>MIC breakpoints (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S ≤</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>0.125</td>
</tr>
<tr>
<td><em>Beta-haemolytic streptococci</em> Groups A, B, C, G</td>
<td>0.25</td>
</tr>
<tr>
<td>Viridans group streptococci (S. <em>anginosus</em> group only)</td>
<td>0.25</td>
</tr>
</tbody>
</table>

S=Susceptible, R=Resistant

Pharmacokinetic/Pharmacodynamic (PK/PD) relationship
The area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) ratio of oritavancin for the infecting organism has been shown to be the parameter that best correlates with efficacy.

Clinical efficacy against specific pathogens
Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to oritavancin in vitro.

Gram-positive micro-organisms:
- *Staphylococcus aureus*
- *Streptococcus pyogenes*
- *Streptococcus agalactiae*
- *Streptococcus dysgalactiae*
- *Streptococcus anginosus* group (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*)

There is no clinical experience in the use of oritavancin to treat infections due to daptomycin-resistant or vancomycin-resistant *S. aureus*.
**Antibacterial activity against other relevant pathogens**
Clinical efficacy has not been established against the following pathogens although *in vitro* studies suggest that they would be susceptible to oritavancin in the absence of acquired mechanisms of resistance:
- Beta-haemolytic streptococci of Group G
- *Clostridium perfringens*
- *Peptostreptococcus spp.*

**Paediatric population**
The European Medicines Agency has deferred the obligation to submit the results of studies with oritavancin in one or more subsets of the paediatric population in the treatment of acute bacterial skin and skin structure infections (see section 4.2 for information on paediatric use).

### 5.2 Pharmacokinetic properties

Oritavancin exhibits linear pharmacokinetics at a dose up to 1,200 mg. The mean (CV%) maximum oritavancin concentration (C<sub>max</sub>) and AUC<sub>0-∞</sub> in patients receiving a single 1,200 mg dose in ABSSSI patients is 138 (23) μg/ml and 2,800 (28.6) μg*h/mL respectively.

**Distribution**
Oritavancin is approximately 85% bound to human plasma proteins. Based on population PK analysis, the population mean total volume of distribution is estimated to be approximately 87.6 L, indicating oritavancin is extensively distributed into the tissues.

Exposures (AUC<sub>0-24</sub>) of oritavancin in skin blister fluid were 20% of those in plasma after a single 800 mg dose in healthy subjects.

**Biotransformation**
No metabolites were observed in plasma or bile from oritavancin treated dogs and rats, respectively. Additionally, *in vitro* human liver microsome studies indicated that oritavancin is not metabolized.

**Elimination**
No mass balance study has been conducted in humans. In humans, less than 1% to 5% of the dose was recovered as parent drug in faeces and urine respectively after 2 weeks of collection indicating that oritavancin is slowly excreted unchanged.

The mean terminal elimination plasma half-life of oritavancin is 245 hours (14.9% CV) based on population PK analysis of ABSSSI patients receiving a single 1,200 mg dose. The population mean total clearance is estimated at 0.445 L/h (27.2% CV).

In a population PK analysis, a relationship between height and clearance was identified, where clearance increased with increasing height. Dose modification based on height is not necessary.

**Special populations**

**Renal impairment**
The pharmacokinetics of oritavancin was examined in the single dose Phase 3 ABSSSI studies in patients with normal renal function, CrCL ≥90 mL/min (n=213), mild renal impairment, CrCL 60-89 mL/min (n=59), moderate renal impairment, CrCL 30-59 mL/min (n=22), and severe renal impairment CrCL <30 mL/min (n=3). Population pharmacokinetic analysis indicated that renal impairment had no clinically relevant effect on the exposure of oritavancin. No dedicated studies in dialysis patients have been conducted. Dosage adjustment of oritavancin is not needed in patients with mild or moderate renal impairment. The pharmacokinetics of oritavancin in patients with severe renal impairment has not been evaluated.

**Hepatic impairment**
The pharmacokinetics of oritavancin were evaluated in a study of subjects with moderate hepatic impairment (Child-Pugh Class B, n=20) and compared with healthy subjects (n=20) matched for gender, age and weight. There were no relevant changes in pharmacokinetics of oritavancin in subjects with moderate hepatic impairment.

Dosage adjustment of oritavancin is not needed in patients with mild and moderate hepatic impairment. The pharmacokinetics of oritavancin in patients with severe hepatic impairment has not been studied.

Effects of age, weight, gender and race
Population PK analysis from the single dose Phase 3 ABSSSI studies in patients indicated that gender, age, weight, or race had no clinically relevant effect on the exposure of oritavancin. No dosage adjustment is warranted in these subpopulations.

5.3 Preclinical safety data

The primary adverse effect of oritavancin administration to rats and dogs was a dose related accumulation of eosinophilic granules in tissue macrophages including hepatocytes, renal cortical epithelial cells, adrenal cells and macrophages of the reticulo endothelial system. The appearance of the eosinophilic granules did not occur following single dose administration and did not significantly affect innate macrophage function in vitro at intracellular levels anticipated from a single 1,200 mg dose.

Moderate, dose-related increases in liver enzymes (alanine transaminase and aspartate transaminase) were observed in rats and dogs and were shown to be reversible upon cessation of treatment. Biochemistry changes associated with kidney function including decreases in urine-specific gravity and pH and slight increases in blood urea nitrogen and sporadic increases in creatinine were present in both rat and dog after treatment of two weeks. Extramedullary haematopoiesis in the spleen was observed in rats. This histopathological finding correlated with an enlargement and an increase in the weight of the spleen. The exposure in rats at the no observed adverse effect level (NOAEL) was less to only slightly higher than the human exposure based on the AUC.

Histamine-like infusion reactions following immediately or shortly after dosing with oritavancin occurred in both rats and dogs. These reactions were associated with mortality at lower dosages in male than in female rats in single dose studies; however, the same gender-related differences were not observed in other species. Studies in neonatal rats and dogs for 30 days showed the same tissue effects as those seen in adult animals including sensitivity to the oritavancin-mediated histamine-like infusion reactions. Mortality was observed in neonatal rats at slightly lower dosage levels than in adults.

A standard battery of in vitro and in vivo tests on the genotoxic potential did not reveal any clinically relevant findings. Lifetime studies in animals have not been conducted to evaluate the carcinogenic potential of oritavancin.

When administered intravenously at doses up to 30 mg/kg, oritavancin did not affect the fertility or reproductive performance of male and female rats. Studies in pregnant rats and rabbits do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. There was no evidence of transplacental transfer of oritavancin in pregnant rats. The exposure in rats at the NOAEL was less to only slightly higher than the human exposure based on the AUC.

Following a single intravenous infusion in lactating rats, radio-labelled \(^{14}C\) oritavancin was excreted in milk and absorbed by nursing pups.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Mannitol
Phosphoric acid (for pH-adjustment)

6.2 Incompatibilities

Sodium chloride solution should not be used for dilution as it is incompatible with oritavancin and may cause precipitation of the medicinal product. Therefore, other intravenous substances, additives or other medicinal products mixed in sodium chloride solution should not be added to oritavancin single-use vials or infused simultaneously through the same intravenous line or through a common intravenous port. In addition, medicinal products formulated at a basic or neutral pH may be incompatible with oritavancin (see section 6.6).

6.3 Shelf life

3 years

After reconstitution
The reconstituted solution should be further diluted in glucose 50 mg/ml (5%) intravenous infusion bag immediately.

After dilution
The diluted solution should be used immediately.

From a microbiological point of view, the product should be used immediately. If not used immediately storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 12 hours at 25°C and 24 hours at 2-8°C following dilution in a glucose 5% intravenous infusion bag, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Do not store above 25°C.

For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Single-use 50 ml Type 1 glass vials with rubber stoppers and aluminium flip off cap.

3 individual vials are packaged in a carton.

6.6 Special precautions for disposal and other handling

For single use only. Orbactiv should be prepared under aseptic techniques in a pharmacy.

The powder must be reconstituted with water for injections and the resulting concentrate must be diluted in a glucose 5% intravenous infusion bag prior to use. Both the reconstituted solution and the diluted solution for infusion should be clear, colourless to pale yellow solution. Parenteral medicinal products should be inspected visually for particulate matter after reconstitution. Aseptic procedures should be used for the preparation of Orbactiv.

Reconstitution: Aseptic technique should be used to reconstitute three Orbactiv 400 mg vials.

- 40 mL of water for injections (WFI) should be added using a sterile syringe to reconstitute each vial to provide a 10 mg/mL solution per vial.
- To avoid excessive foaming, it is recommended that WFI should be added carefully, along the walls of the vials.
• Each vial should be swirled gently to avoid foaming and ensure that all of the powder is completely reconstituted in solution.

**Dilution:** Three reconstituted vials are needed for dilution for administration of a single 1,200 mg intravenous infusion. Only glucose 5% intravenous bag (D5W) should be used for dilution. Sodium chloride solution should not be used for dilution (see section 6.2).

To dilute:

• Withdraw and discard 120 mL from a 1,000 mL D5W intravenous bag.
• Withdraw 40 mL from each of the three reconstituted vials and add to D5W intravenous bag to bring the bag volume to 1,000 mL. This yields a concentration of 1.2 mg/mL of oritavancin. PP (Polypropylene) or PVC (Polyvinyl chloride) bags should be used for administration preparation.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. **MARKETING AUTHORISATION HOLDER**

The Medicines Company UK Ltd
115L Milton Park
Abingdon
Oxfordshire
OX14 4SA
UNITED KINGDOM

8. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/15/989/001

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: {DD month YYYY}

10. **DATE OF REVISION OF THE TEXT**

ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Hälsa Pharma GmbH
Nikolaus Dürkopp Straße 4a
D-33602 Bielefeld
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
ANNEX III

LABELLING AND PACKAGE LEAFLET
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Orbactiv 400 mg powder for concentrate for solution for infusion
oritavancin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains oritavancin diphosphate equivalent to 400 mg oritavancin
After reconstitution and dilution, 1 ml solution for infusion contains 1.2 mg oritavancin

3. LIST OF EXCIPIENTS

Mannitol
Phosphoric acid

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for concentrate for solution for infusion
3 vials

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Intravenous use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

The Medicines Company UK Ltd
115L Milton Park, Abingdon
Oxfordshire OX14 4SA
UNITED KINGDOM

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/989/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted
1. NAME OF THE MEDICINAL PRODUCT

Orbactiv 400 mg powder for concentrate
oritavancin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Contains 400 mg oritavancin

3. LIST OF EXCIPIENTS

Mannitol
Phosphoric acid

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for concentrate

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Intravenous use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

The Medicines Company UK Ltd
115L Milton Park, Abingdon
Oxfordshire OX14 4SA
UNITED KINGDOM

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/989/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Orbactiv 400 mg powder for concentrate for solution for infusion
Oritavancin

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Orbactiv is and what it is used for
2. What you need to know before you are given Orbactiv
3. How you will be given Orbactiv
4. Possible side effects
5. How to store Orbactiv
6. Contents of the pack and other information

1. What Orbactiv is and what it is used for

Orbactiv is an antibiotic that contains the active substance oritavancin. Oritavancin is a type of antibiotic (a lipoglycopeptide antibiotic) that can kill or stop the growth of certain bacteria.

Orbactiv is used to treat infections of the skin and underlying tissues.

It is for use in adults only.

Orbactiv can only be used to treat infections caused by bacteria known as Gram positive bacteria. In mixed infections where other types of bacteria are suspected, your doctor will give you other appropriate antibiotics together with Orbactiv.

2. What you need to know before you are given Orbactiv

You must not be given Orbactiv
- if you are allergic to oritavancin or any of the other ingredients of this medicine (listed in section 6).
- if it is expected that you may need to be given unfractionated heparin sodium (a blood thinning medicine) within 48 h of the dose of Orbactiv.

Warnings and precautions

Talk to your doctor or nurse before receiving Orbactiv if you:
• have ever had an allergic reaction to another glycopeptide antibiotic (such as vancomycin and telavancin)
• have developed severe diarrhoea during or following antibiotic treatment in the past.
• have or are suspected to have a bone infection caused by bacteria (osteomyelitis). Your doctor will treat you as necessary.

Since Orbactiv is given as an infusion (drip) into a vein, you may get reactions where the needle is inserted, including itching.
Orbactiv may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading.

While antibiotics, including Orbactiv, fight certain bacteria, they may not be active against other bacteria or fungi, which may therefore continue to grow. This is called overgrowth. Your doctor will monitor you in case this happens and treat you if necessary.

After being given Orbactiv, you may get a new infection at another site on your skin. Your doctor should monitor you in case this happens and treat you as necessary.

**Children and adolescents**
Orbactiv should not be used in children or adolescents.

**Other medicines and Orbactiv**
Tell your doctor if you are using, have recently used or might use any other medicines.

It is particularly important to tell your doctor if you are using medicines that prevent blood from clotting (oral anticoagulants, e.g. warfarin). Your doctor may need to monitor your blood clotting times.

If you are going to be given a blood thinner called unfractionated heparin, then tell your doctor if you have received Orbactiv within the last 48 hours.

**Pregnancy and breast-feeding**
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.

You should not be given this medicine during pregnancy unless the benefit is considered to be greater than the risk to the baby.

**Driving and using machines**
Orbactiv may cause dizziness, which can influence your ability to drive or operate machines.

3. **How you will be given Orbactiv**

Orbactiv will be given to you by your doctor or nurse, by infusion (drip) into a vein.

The recommended dose for Orbactiv is one single infusion of 1,200 mg administered into a vein over 3 hours.

**If you are given more Orbactiv than you should**
Your doctor will decide how to treat you, including stopping the treatment and monitoring for signs of ill effects.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Tell your doctor or nurse immediately if you experience a reaction to the infusion including any of the following symptoms:**
- Redness in the face or other areas of the skin;
- Wheezing;
- Shortness of breath;
- Swelling around throat or under the skin that develops over a short period of time;
- Shivering or trembling;
- Rapid or weak pulse;
• Hives;
• Itching;
• Chest pain or tightness;
• Low blood pressure.

**Common side effects (may affect up to 1 in 10 patients):**
• Fewer red blood cells or less haemoglobin than normal;
• Feeling dizzy;
• Headache;
• Feeling sick (nausea) or being sick (vomiting);
• Diarrhoea;
• Constipation;
• Pain or irritation where the injection was given;
• Itching, skin rash;
• Muscle pain;
• More enzymes produced by your liver (as shown in blood tests);
• Heart racing or beating fast;
• Infection getting worse or new infection at another site on your skin;
• Swollen, red area of skin or underneath skin that feels hot and tender;
• Accumulation of pus underneath the skin.

**Uncommon side effects (may affect up to 10 in 1,000 patients):**
• Higher than normal levels of eosinophils, a type of white blood cell (eosinophilia);
• Low blood sugar;
• High uric acid levels in the blood;
• Increased blood bilirubin levels;
• Severe rash;
• Flushing;
• Inflammation surrounding a tendon (known as tenosynovitis);
• Bone infection caused by bacteria (known as osteomyelitis);
• Reduced blood platelet count below the normal lower limit (known as thrombocytopenia).

**Reporting of side effects**
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Orbactiv**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.
Do not store above 25°C.

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information

What Orbactiv contains
- The active substance is oritavancin. Each vial contains oritavancin diphosphate equivalent to 400 mg oritavancin.
- The other ingredients are mannitol and phosphoric acid.

What Orbactiv looks like and contents of the pack
- Orbactiv is a powder for concentrate for solution for infusion
- Orbactiv is a white to off white powder, supplied in a 50 ml glass vial.
- Orbactiv is available in cartons containing 3 vials.

Marketing Authorisation Holder

The Medicines Company UK Ltd
115L Milton Park
Abingdon
Oxfordshire
OX14 4SA
United Kingdom

Manufacturer

HÄLSA Pharma GmbH
Nikolaus Dürkopp Straße 4a
D-33602 Bielefeld
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
The Medicines Company UK Ltd
Tel/Tel : +32 (0) 80081522
ou/oder +32 (0) 27006752
Email/E-Mail :
medical.information@themedco.com

**Lietuva**
The Medicines Company UK Ltd
Tel. Nr.: +370 880031794
arba +370 852140678
El. paštas: medical.information@themedco.com

**България**
The Medicines Company UK Ltd
Тел.: 00800 1103246
или +359(0) 24916041
e-mail: medical.information@themedco.com

**Luxembourg/Luxemburg**
The Medicines Company UK Ltd
Tél/Tel : +352 80028211
ou/oder +352 24871691
Email/E-Mail :
medical.information@themedco.com

**Česká republika**
The Medicines Company UK Ltd
Tel.: +420 800050070
nebo +420 239018449
E-mail: medical.information@themedco.com

**Magyarország**
The Medicines Company UK Ltd
Tel. : +36 (0) 680986235
vagy +36 (0) 617777410
E-mail : medical.information@themedco.com

**Danmark**
The Medicines Company UK Ltd
Tlf.nr.: +45 80251618
eller +45 43314966
E-mail : medical.information@themedco.com

**Malta**
The Medicines Company UK Ltd
Tel : +356 80062399
jew +356 27780987
Email : medical.information@themedco.com
Deutschland
The Medicines Company UK Ltd
Tel.: +49 (0) 8007238819
oder +49 (0) 69299571318
E-Mail: medical.information@themedco.com

Nederland
The Medicines Company UK Ltd
Tel.: +31 (0) 8003712001
of +31 (0) 707709201
Email: medical.information@themedco.com

Österreich
The Medicines Company UK Ltd
Tel.: +43 (0) 800070265
oder +43 (0) 120692417
E-Mail: medical.information@themedco.com

España
The Medicines Company UK Ltd
Tel.: +34 900816435
o: +34 912768731
E-mail: medical.information@themedco.com

Polska
The Medicines Company UK Ltd
Tel.: 800702695
lub +48 223060790
E-mail: medical.information@themedco.com

Ελλάδα
The Medicines Company UK Ltd
Τηλ: +30 0080044149444
ή: +30 2130022586
E-mail: medical.information@themedco.com

România
The Medicines Company UK Ltd
Tel: 00800 843 633 26
sau +41 44 828 1084
E-mail: medical.information@themedco.com

Italia
The Medicines Company UK Ltd
Tel: +39 800979546
o +39 (0)291294790
Email: medical.information@themedco.com

Slovenija
The Medicines Company UK Ltd
Tel.: +386 (0) 80080631
ali +386 (0) 18888602
E-pošta: medical.information@themedco.com

Slovenská republika
The Medicines Company UK Ltd
Tel.: +421 0800606758
alebo +421 (0) 268622610
Email: medical.information@themedco.com

Italia
The Medicines Company UK Ltd
Tel: +39 800979546
o +39 (0)291294790
Email: medical.information@themedco.com

Suomi/Finnland
The Medicines Company UK Ltd
Puh./tel. +358 (0) 800774218
tai +358 (0) 972519943
S-posti: medical.information@themedco.com
The following information is intended for healthcare professionals only:

Orbactiv is intended for intravenous (IV) administration, only after reconstitution and dilution. Three Orbactiv 400 mg vials need to be reconstituted and diluted to prepare a single once-only 1,200 mg IV dose. Orbactiv should be prepared under aseptic techniques in a pharmacy.

The powder must be reconstituted with water for injections and the resulting concentrate must be diluted in a glucose 5\% intravenous infusion bag prior to use. Both the reconstituted solution and the diluted solution for infusion should be clear, colourless to pale yellow solution. Parenteral medicinal products should be inspected visually for particulate matter after reconstitution. Aseptic procedures should be used for the preparation of Orbactiv.

Reconstitution: Aseptic technique should be used to reconstitute three Orbactiv 400 mg vials.

- 40 mL of water for injections (WFI) should be added using a sterile syringe to reconstitute each vial to provide a 10 mg/mL solution per vial.
- To avoid excessive foaming, it is recommended that WFI should be added carefully, along the walls of the vials.
- Each vial should be swirled gently to avoid foaming and ensure that all Orbactiv powder is completely reconstituted in solution.

The reconstituted solution should be further diluted in glucose 5\% intravenous infusion bag immediately.

Dilution: Three reconstituted vials are needed for dilution for administration of a single 1,200 mg IV infusion. Only glucose 5\% intravenous bag (D5W) should be used for dilution.

To dilute:

- Withdraw and discard 120 mL from a 1,000 mL D5W intravenous bag.
Withdraw 40 mL from each of the three reconstituted vials and add to D5W intravenous bag to bring the bag volume to 1,000 mL. This yields a concentration of 1.2 mg/mL of oritavancin. PP (Polypropylene) or PVC (Polyvinyl chloride) bags should be used for administration preparation. The diluted solution should be used immediately.

From a microbiological point of view, the product should be used immediately. If not used immediately, storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 12 hours at 25°C and 24 hours at 2-8°C for Orbactiv diluted in glucose 5% intravenous infusion bag, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.